Lv1
22 积分 2021-10-04 加入
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
4天前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
4天前
已完结
VEGF signaling: Role in angiogenesis and beyond
3个月前
已完结
The landscape of cancer research and cancer care in China
3个月前
已完结
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study
3个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3个月前
已完结
TGF-β mediated drug resistance in solid cancer
3个月前
已完结
TGF-β-driven EMT in cancer progression and drug resistance
3个月前
已完结
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
3个月前
已完结
皖公网安备34019202002308
